Key Take Away :
This webinar will provide an overview of the federal and state laws that are designed to allow terminally ill patients access to investigational products.
Overview :
The webinar will review the legal framework of FDA鈥檚 expanded access regulations and the recent initiative to pass 鈥楻ight to Try鈥� laws at the state level, which are designed to allow patients access to investigational treatments without the need for FDA approval.
The webinar will provide the historical context of challenges to FDA鈥檚 authority to regulate access to investigational drugs by seriously ill patients who do not qualify for an ongoing clinical and for whom there is no approved therapy, and the ensuing development of the 鈥楻ight to Try鈥� initiative.
An update on the number of states that have passed 鈥楻ight to Try鈥� laws will be provided and the similarities and differences between the various state laws will be reviewed.
The webinar will explore legal tension between the FDA regulations and the state 鈥楻ight to Try鈥� laws, and the latest efforts to pass a National 鈥楻ight to Try鈥� Law.
Why Should You Attend :
Personal autonomy is at the heart of the tension between the FDA鈥檚 expanded access regulations and the 鈥楻ight to Try鈥� initiative.
FDA鈥檚 expanded access regulations seek to provide seriously ill patients with access to investigational new drugs in a manner that is designed to ensure the potential benefit to the individual patient justifies the potential risks posed by the use of the investigational drug outside the context of an ongoing clinical trial and which preserves the integrity of the clinical trial system for the development of new drugs.
But for seriously ill patients, the prospect of trying to comply with government regulations while fighting to save their lives can be viewed as an unreasonable burden established by an over reaching and paternalistic government. Clinicians, hospitals, and institutional review boards (IRBs) need to understand both the federal and state laws and the tension between them, so they are prepared to address requests from seriously ill patients for access to investigational drugs. Members of the pharmaceutical industry need to understand the potential legal, business, and financial risks of providing, or not providing, access to their investigational drugs to an individual patient.
Areas Covered In This Webinar :
The webinar will review FDA鈥檚 current legal framework for providing seriously ill patients access to investigational new drugs outside the context of an ongoing clinical trial. The legal challenges to FDA鈥檚 authority will be reviewed.
The advent of the recent 鈥楻ight to Try鈥� initiative to pass state laws providing patients access to investigational drugs without FDA oversight will be discussed. An update on the number of states that have passed 鈥楻ight To Try鈥� laws will be provided along with an analysis of the similarities and differences in the individual state laws.
The implications for companies in providing access to their investigational products will be outlined and will include a review of the policy considerations that must be made in determining whether to provide access to an investigational product outside the context of a clinical trial.
The impact and implications of the use of broadcast and social media by individuals seeking access to an investigational drug on companies and FDA will be reviewed.
Learning Objectives :
Understanding FDA鈥檚 current legal framework for gaining access to investigational drugs outside the context of a clinical trial and the advent of state laws designed to remove FDA from the process
To understand the implications for members of the pharmaceutical industry in responding to individual requests for access to their investigational products
Explore the policy considerations involved in developing a legal framework for providing individuals access to investigational products outside the context of the clinical trials
Who Will Benefit :
Executives in the Pharmaceutical Industry
In-house Counsel
Outside Counsel
Scientific Community
Institutional Review Boards
Compliance Officers
For more information, please visit : https://www.atozcompliance.com/trainings-webinar/life-sciences/pharmaceuticals/terminally-ill-patients-the-right-to-try/kate-duffy-mazan/300168
Email: support@atozcompliance.com
Toll Free: +1- 844-414-1400
Tel: +1-516-900-5509
Level:
Intermediate
Speakers Profile :
Kate Duffy Mazan
Kate Duffy Mazan is an attorney in private practice in McLean, VA. She is the founding member of The Clinical Technology Transfer Group (CTTG). CTTG is a law firm concentrating in technology transfer and regulatory compliance in the clinical setting.
Kate has extensive experience in the negotiation of Cooperative Research and Development Agreements (CRADAs). Prior to entering private practice, Kate worked for nine years at the National Cancer Institute (NCI) within the National Institutes of Health. As a technology transfer professional at NIH she managed the intellectual property portfolio of NCI鈥檚 Natural Products Branch, negotiating CRADAs and international agreements with countries in Africa, Central and South America, and the Pacific rim.
Kate also served as the Coordinator, of the Client Centers Unit in NCI鈥檚 Office of Technology Development, where she managed and directed the technology development activities for the Office of the Director of the National Cancer Institute and six 鈥渃lient" Institutes. Primary responsibilities included training and management of staff responsible for negotiating a wide variety of technology transfer agreements including Cooperative Research and Development Agreements (CRADAs), Clinical Trial Agreements, Material Transfer Agreements (MTAs) and Confidential Disclosure Agreements (CDAs). Kate began her career at NIH as Chief of NCI鈥檚 Cancer Information Service (CIS), a nationwide network of cancer information and education programs located at major cancer centers across the country. In that capacity she was responsible for developing a training program on the conduct of clinical trials to assist information specialists explain clinical research to patients and the public.
Since entering into private practice in 1997, Kate has assisted a variety of companies in the negotiation of CRADAs, government licenses and other technology transfer agreements with the federal government. Her practice also includes a heavy emphasis on clinical research. She and her staff provide transactional and regulatory support to pharmaceutical, biotech, medical device, and dietary supplement companies in the US and around the world conducting clinical research. CTTG provides high volume contracting services for companies conducting clinical trials and as well as regulatory assistance on informed consent, HIPAA, and Good Clinical Practice requirements.
Kate holds a law degree from the Columbus School of Law at the Catholic University of America, Washington, D.C., a Master of Science in Public Health Administration from the University of Massachusetts Amherst, and an A.B. from Stonehill College, North Easton, Massachusetts. Kate is admitted to practice law in Virginia, Maryland, and the District of Columbia.
This webinar will provide an overview of the federal and state laws that are designed to allow terminally ill patients access to investigational products.
Overview :
The webinar will review the legal framework of FDA鈥檚 expanded access regulations and the recent initiative to pass 鈥楻ight to Try鈥� laws at the state level, which are designed to allow patients access to investigational treatments without the need for FDA approval.
The webinar will provide the historical context of challenges to FDA鈥檚 authority to regulate access to investigational drugs by seriously ill patients who do not qualify for an ongoing clinical and for whom there is no approved therapy, and the ensuing development of the 鈥楻ight to Try鈥� initiative.
An update on the number of states that have passed 鈥楻ight to Try鈥� laws will be provided and the similarities and differences between the various state laws will be reviewed.
The webinar will explore legal tension between the FDA regulations and the state 鈥楻ight to Try鈥� laws, and the latest efforts to pass a National 鈥楻ight to Try鈥� Law.
Why Should You Attend :
Personal autonomy is at the heart of the tension between the FDA鈥檚 expanded access regulations and the 鈥楻ight to Try鈥� initiative.
FDA鈥檚 expanded access regulations seek to provide seriously ill patients with access to investigational new drugs in a manner that is designed to ensure the potential benefit to the individual patient justifies the potential risks posed by the use of the investigational drug outside the context of an ongoing clinical trial and which preserves the integrity of the clinical trial system for the development of new drugs.
But for seriously ill patients, the prospect of trying to comply with government regulations while fighting to save their lives can be viewed as an unreasonable burden established by an over reaching and paternalistic government. Clinicians, hospitals, and institutional review boards (IRBs) need to understand both the federal and state laws and the tension between them, so they are prepared to address requests from seriously ill patients for access to investigational drugs. Members of the pharmaceutical industry need to understand the potential legal, business, and financial risks of providing, or not providing, access to their investigational drugs to an individual patient.
Areas Covered In This Webinar :
The webinar will review FDA鈥檚 current legal framework for providing seriously ill patients access to investigational new drugs outside the context of an ongoing clinical trial. The legal challenges to FDA鈥檚 authority will be reviewed.
The advent of the recent 鈥楻ight to Try鈥� initiative to pass state laws providing patients access to investigational drugs without FDA oversight will be discussed. An update on the number of states that have passed 鈥楻ight To Try鈥� laws will be provided along with an analysis of the similarities and differences in the individual state laws.
The implications for companies in providing access to their investigational products will be outlined and will include a review of the policy considerations that must be made in determining whether to provide access to an investigational product outside the context of a clinical trial.
The impact and implications of the use of broadcast and social media by individuals seeking access to an investigational drug on companies and FDA will be reviewed.
Learning Objectives :
Understanding FDA鈥檚 current legal framework for gaining access to investigational drugs outside the context of a clinical trial and the advent of state laws designed to remove FDA from the process
To understand the implications for members of the pharmaceutical industry in responding to individual requests for access to their investigational products
Explore the policy considerations involved in developing a legal framework for providing individuals access to investigational products outside the context of the clinical trials
Who Will Benefit :
Executives in the Pharmaceutical Industry
In-house Counsel
Outside Counsel
Scientific Community
Institutional Review Boards
Compliance Officers
For more information, please visit : https://www.atozcompliance.com/trainings-webinar/life-sciences/pharmaceuticals/terminally-ill-patients-the-right-to-try/kate-duffy-mazan/300168
Email: support@atozcompliance.com
Toll Free: +1- 844-414-1400
Tel: +1-516-900-5509
Level:
Intermediate
Speakers Profile :
Kate Duffy Mazan
Kate Duffy Mazan is an attorney in private practice in McLean, VA. She is the founding member of The Clinical Technology Transfer Group (CTTG). CTTG is a law firm concentrating in technology transfer and regulatory compliance in the clinical setting.
Kate has extensive experience in the negotiation of Cooperative Research and Development Agreements (CRADAs). Prior to entering private practice, Kate worked for nine years at the National Cancer Institute (NCI) within the National Institutes of Health. As a technology transfer professional at NIH she managed the intellectual property portfolio of NCI鈥檚 Natural Products Branch, negotiating CRADAs and international agreements with countries in Africa, Central and South America, and the Pacific rim.
Kate also served as the Coordinator, of the Client Centers Unit in NCI鈥檚 Office of Technology Development, where she managed and directed the technology development activities for the Office of the Director of the National Cancer Institute and six 鈥渃lient" Institutes. Primary responsibilities included training and management of staff responsible for negotiating a wide variety of technology transfer agreements including Cooperative Research and Development Agreements (CRADAs), Clinical Trial Agreements, Material Transfer Agreements (MTAs) and Confidential Disclosure Agreements (CDAs). Kate began her career at NIH as Chief of NCI鈥檚 Cancer Information Service (CIS), a nationwide network of cancer information and education programs located at major cancer centers across the country. In that capacity she was responsible for developing a training program on the conduct of clinical trials to assist information specialists explain clinical research to patients and the public.
Since entering into private practice in 1997, Kate has assisted a variety of companies in the negotiation of CRADAs, government licenses and other technology transfer agreements with the federal government. Her practice also includes a heavy emphasis on clinical research. She and her staff provide transactional and regulatory support to pharmaceutical, biotech, medical device, and dietary supplement companies in the US and around the world conducting clinical research. CTTG provides high volume contracting services for companies conducting clinical trials and as well as regulatory assistance on informed consent, HIPAA, and Good Clinical Practice requirements.
Kate holds a law degree from the Columbus School of Law at the Catholic University of America, Washington, D.C., a Master of Science in Public Health Administration from the University of Massachusetts Amherst, and an A.B. from Stonehill College, North Easton, Massachusetts. Kate is admitted to practice law in Virginia, Maryland, and the District of Columbia.
